Advances in Molecular Pathology and Treatment of Breast Cancer
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 2825
Special Issue Editor
Interests: breast cancer; thoracic oncology; precision medicine; molecular pathology; antibody-drug conjugates (ADCs); immunotherapy; liquid biopsy (ctDNA); oligometastatic disease; clinical guidelines
Special Issue Information
Dear Colleagues,
The landscape of breast cancer management is being radically reshaped by discoveries in molecular pathology. Understanding the intricate biology of different subtypes, HR+/HER2−, HER2+, and TNBC, is no longer just prognostic but now fundamentally directive for therapy. From the development of novel ADCs and targeted agents to the integration of liquid biopsy for dynamic monitoring, these advances promise a more personalized and effective approach for patients across all disease stages. This Special Issue seeks to capture this pivotal moment of translation from molecular insight to clinical practice.
This Special Issue aims to provide a comprehensive forum for disseminating cutting-edge research on the integration of molecular pathology into all facets of breast cancer care. It aligns perfectly with the scope of the International Journal of Molecular Sciences by focusing on the molecular mechanisms driving the disease and the therapeutic innovations they inspire. We welcome contributions that explore how molecular profiling guides decisions in neoadjuvant, adjuvant, and metastatic settings, and how it helps in de-escalating or sequencing therapies to improve patient outcomes.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Molecular subtyping and its therapeutic implications in HR+/HER2−, HER2+, and TNBC.
- The role of novel biomarkers, molecular signatures, and ctDNA in prognosis and treatment guidance.
- The mechanism of action, efficacy, and resistance to next-generation ADCs.
- Strategies for chemotherapy de-escalation through rational targeted combinations.
- Management of oligometastatic disease based on molecular profile.
- Novel targeted therapies for rare molecular subsets (ESR1, PIK3CA, BRCA mutations, HER2-low).
- Mechanisms of resistance to endocrine therapy, CDK4/6 inhibitors, and immunotherapy.
- Translational studies bridging molecular pathology with clinical trial outcomes.
We look forward to receiving your contributions.
Dr. Nabil Ismaili
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- molecular pathology
- precision medicine
- antibody-drug conjugates (ADCs)
- circulating tumor DNA (ctDNA)
- targeted therapy
- immunotherapy
- treatment resistance
- oligometastatic disease
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
